Report

Renaissance BioScience - RNAi technology from bioengineered yeast

Renaissance BioScience is a private bioengineering company developing proprietary yeast strains for use in the food and beverage, healthcare and agriculture industries. It has been successful in commercially licensing its ‘Generation 1’ technology, which comprises yeast strains for use in the food and beverage industry. The primary focus has now shifted to the development of its ‘Generation 2’ technology – yeast strains capable of producing and delivering RNAi – and aims to address challenges in the agriculture and biopharmaceutical industries. Early results indicate that its RNAi solutions could be low-cost, efficacious and non-toxic. As the company is a private entity, we have limited visibility on its financials. However, in November 2021, it successfully closed the balance of its US$5m convertible debenture, proceeds from which have been allocated to advance its RNAi platform.
Underlying
Renaissance BioScience

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Sean Conroy

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch